Brian Pelkowski has been at Genentech for over four years. He moved into his current role as the Rituxan for RA Strategy Lead at the start of this year. Prior to this transition, Brian spent two years leading the Market Planning group responsible for assessing the commercial value and recommending the commercial strategy for internal and external oncology development opportunities. Additionally, Brian’s group provided the Rituxan Hem/Onc team with recommendations and analysis on the hematology marketplace and the opportunities for sustained growth. Before joining Genentech, Brian spent over six years as a consultant to pharmaceutical and biotechnology companies working on valuations, mergers and asset allocation projects. Brian received an MBA from the Kellogg School of Management.
After a brief history of Genentech and its founding, we will walk through the current products, what has made Genentech an award-winning company to work for, and through my personal journey over the past four years, a view into what lies ahead for Genentech.
